Rep. Gilbert Ray Cisneros, Jr. Sells Medpace Holdings, Inc. (NASDAQ:MEDP) Shares

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Medpace Holdings, Inc. (NASDAQ:MEDP). In a filing disclosed on February 13th, the Representative disclosed that they had sold between $15,001 and $50,000 in Medpace stock on January 15th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Hermès International Société en commandite par actions (OTCMKTS:HESAF) on 2/3/2026.
• Purchased $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 2/3/2026.
• Purchased $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 2/3/2026.
• Purchased $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 2/3/2026.
• Purchased $1,001 – $15,000 in shares of Banco Santander (NYSE:SAN) on 2/3/2026.
• Purchased $1,001 – $15,000 in shares of Leonardo (OTCMKTS:FINMF) on 2/3/2026.
• Purchased $1,001 – $15,000 in shares of Costco Wholesale (NASDAQ:COST) on 1/30/2026.
• Purchased $1,001 – $15,000 in shares of Transdigm Group (NYSE:TDG) on 1/30/2026.
• Purchased $1,001 – $15,000 in shares of Cloudflare (NYSE:NET) on 1/30/2026.
• Purchased $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 1/30/2026.

Medpace Stock Up 0.3%

Shares of Medpace stock traded up $1.19 during trading on Tuesday, hitting $429.22. 180,180 shares of the stock traded hands, compared to its average volume of 336,352. The stock has a market cap of $12.18 billion, a price-to-earnings ratio of 28.05, a PEG ratio of 2.05 and a beta of 1.42. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $628.92. The firm’s fifty day moving average is $565.10 and its 200-day moving average is $539.07.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The business had revenue of $708.45 million for the quarter, compared to analysts’ expectations of $689.53 million. During the same period last year, the business earned $3.67 earnings per share. The business’s quarterly revenue was up 32.0% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Activity at Medpace

In related news, CFO Kevin M. Brady sold 3,000 shares of the stock in a transaction on Friday, November 21st. The stock was sold at an average price of $590.35, for a total transaction of $1,771,050.00. Following the sale, the chief financial officer directly owned 6,000 shares of the company’s stock, valued at $3,542,100. This trade represents a 33.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the transaction, the vice president owned 27,500 shares in the company, valued at $16,751,625. This represents a 42.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 257,295 shares of company stock valued at $155,300,319 over the last 90 days. Corporate insiders own 20.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on MEDP shares. Leerink Partners decreased their target price on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 11th. Robert W. Baird raised shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price objective for the company in a research note on Tuesday, February 10th. Zacks Research cut Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Truist Financial lowered their price target on Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a research report on Wednesday, February 11th. Finally, Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Four equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $487.36.

Hedge Funds Weigh In On Medpace

Large investors have recently made changes to their positions in the business. AQR Capital Management LLC raised its stake in Medpace by 65.1% during the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after buying an additional 404,226 shares during the last quarter. Norges Bank purchased a new position in shares of Medpace in the 2nd quarter worth about $66,597,000. Arrowstreet Capital Limited Partnership raised its position in shares of Medpace by 205.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after purchasing an additional 211,411 shares during the last quarter. Franklin Resources Inc. increased its stake in Medpace by 158.6% during the 4th quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock valued at $168,198,000 after purchasing an additional 183,645 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in Medpace by 92.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock worth $194,920,000 after buying an additional 166,654 shares during the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.